List view / Grid view
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
A team has shown that removing the inflammatory signalling protein TNF in a laboratory model prevented stomach cancers from becoming severe.
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
Scientists have found that the RFWD3 protein could play a role in recruiting DNA key repair and signalling factors, impacting chemotherapy.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Next-generation sequencing will be employed to study 1,500 plasma proteins in participants, according to UK Biobank.
